Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119362) titled 'A Study on the Efficacy and Safety of Sintilimab Combined with Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients with Short-term Recurrence after Adjuvant Therapy' on Feb. 26.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Gastric cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-03-01
Target Sample Size: Trial Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=30...